APA (7th ed.) Citation

Palit, S. A. L., Dorp, J. v., Vis, D., Lieftink, C., Linder, S., Beijersbergen, R., . . . Heijden, M. S. v. d. (2021). A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer. Nature Portfolio.

Chicago Style (17th ed.) Citation

Palit, Sander A. L., Jeroen van Dorp, Daniel Vis, Cor Lieftink, Simon Linder, Roderick Beijersbergen, Andries M. Bergman, Wilbert Zwart, and Michiel S. van der Heijden. A Kinome-centered CRISPR-Cas9 Screen Identifies Activated BRAF to Modulate Enzalutamide Resistance with Potential Therapeutic Implications in BRAF-mutated Prostate Cancer. Nature Portfolio, 2021.

MLA (8th ed.) Citation

Palit, Sander A. L., et al. A Kinome-centered CRISPR-Cas9 Screen Identifies Activated BRAF to Modulate Enzalutamide Resistance with Potential Therapeutic Implications in BRAF-mutated Prostate Cancer. Nature Portfolio, 2021.